[HTML] frontiersin.org

[HTML][HTML] Discovery of novel biomarkers of therapeutic responses in Han Chinese pemetrexed-based treated advanced NSCLC patients

X Zhang, D Zhang, L Huang, G Li, L Chen… - Frontiers in …, 2019 - frontiersin.org
Pemetrexed, one of the most commonly used drugs in advanced non–small cell lung cancer
(NSCLC) therapies, often leads to various therapeutic responses in patients. These …
被引用次数：18 相关文章
[HTML] nih.gov

[HTML][HTML] Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients

X Zhang, D Zhang, L Huang, G Li, L Chen… - Frontiers in …, 2019 - ncbi.nlm.nih.gov
Pemetrexed, one of the most commonly used drugs in advanced non–small cell lung cancer
(NSCLC) therapies, often leads to various therapeutic responses in patients. These …

Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients.

X Zhang, D Zhang, L Huang, G Li, L Chen… - Frontiers in …, 2019 - europepmc.org
Pemetrexed, one of the most commonly used drugs in advanced non–small cell lung cancer
(NSCLC) therapies, often leads to various therapeutic responses in patients. These …

Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients

X Zhang, D Zhang, L Huang, G Li… - Frontiers in …, 2019 - pubmed.ncbi.nlm.nih.gov
Pemetrexed, one of the most commonly used drugs in advanced non-small cell lung cancer
(NSCLC) therapies, often leads to various therapeutic responses in patients. These …